Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -22.5%
- Operating Margin Trend +5.81 pp/yr
TNGX
Tango Therapeutics, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -28.9%
- 5yr Share-Count CAGR 16.9%
Growth Quality
Weight: 35%
B-
63
- 5yr Revenue CAGR 13.9%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 4/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -300.2%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
C
55
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 31.22
Stability
Weight: 5%
B
72
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 2
- Negative-Revenue Years (5) 1/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 2 new buys; 1 trimmed; 1 full exit.
- Holders
- 3 +1
- Avg Δ position
- -73.0%
- New buys
- 2
- Full exits
- 1
- Cooperman sold -100%
- Greenblatt new
- Laffont new